CorMedix (CRMD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

CorMedix

NasdaqGM•Healthcare•Biotechnology

$7.82+0.06(0.01%)Pre-market

Market Cap

$613.43M

P/E

3.3x

P/S

1.3x

P/B

1.3x

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

How this company scores

ExcellentMetricSide Score: 82/100

Strongest: Cash & Earnings Quality (23/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability22/25

Growth22/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality23/25

Strengths

Growing revenueRising free cash flowStrong marginsHigh ROE

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 3.3x5y range 2.9x – 23.4x

Currently below its 6-quarter median.

P/S · 1.3x5y range 1.3x – 7044.9x

Currently below its 18-quarter median.

P/B · 1.3x5y range 1.2x – 8.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $613.43M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $462.25M
Q. Revenue: $101.93M
TTM EBITDA: $252.35M
TTM Op. Income: $217.04M
Q. Op. Income: $42.91M
TTM Net Income: $187.17M
Q. Net Income: $25.99M
EPS: $0.33
Shares Out.: $78.44M

$462.25M in TTM revenue grew 280.5% YoY, reaching $101.93M last quarter. TTM EBITDA of $252.35M and TTM operating income of $217.04M show growth is flowing through to the bottom line. TTM net income of $187.17M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 75.7%
EBITDA Margin: 52.4%
Op. Margin: 42.1%
Net Margin: 25.5%

Op. margin of 42.1% is down 7.1% YoY — costs are rising relative to revenue. Net margin at 25.5% and gross margin of 75.7% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 14% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 3.3x
P/S Ratio: 1.3x
P/B Ratio: 1.3x

At 3.3x P/E, the stock trades below typical market levels. P/S of 1.3x and P/B of 1.3x provide additional context. P/E sits below typical market levels while revenue is growing. Over the past year, P/E is down 80% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $904.05M
Cash: $256.69M
Long-Term Debt: N/A
Book Value: $460.83M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $86.24M
TTM Free Cash Flow: $250.42M
FCF Margin: 54.2%
FCF / Net Income: 1.3

TTM FCF of $250.42M on $86.24M in operating cash flow. The FCF / Net Income ratio of 1.3x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 7 consecutive quarters — an improving trend.